UB Paderborn / Katalog / Suche / in CDI

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Cancer cell, 2019-05, Vol.35 (5), p.738-751.e9

2019

Link zum Volltext

Verfügbarkeit prüfen

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Molecular cancer therapeutics, 2015-09, Vol.14 (9), p.2023-2034

2015

Link zum Volltext

Verfügbarkeit prüfen

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Bioorganic & medicinal chemistry letters, 2022-10, Vol.74, p.128929-128929, Article 128929

2022

Link zum Volltext

Verfügbarkeit prüfen

Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors

Journal of medicinal chemistry, 1992-07, Vol.35 (14), p.2562-2572

1992

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A (ETA) Receptor-Selective Antagonists

Journal of medicinal chemistry, 1995-04, Vol.38 (8), p.1259-1263

1995

Link zum Volltext

Verfügbarkeit prüfen

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Bioorganic & medicinal chemistry letters, 2010-10, Vol.20 (19), p.5793-5798

2010

Link zum Volltext

Verfügbarkeit prüfen

Characterization of [ 125 I]‐PD164333, an ET A selective non‐peptide radiolabelled antagonist, in normal and diseased human tissues

British journal of pharmacology, 2009-02, Vol.123 (2), p.223-230

2009

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of lipoprotein(a) assembly

Bioorganic & medicinal chemistry, 2003-11, Vol.11 (22), p.4827-4845

2003

Link zum Volltext

Verfügbarkeit prüfen

Structure−Activity Relationships in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists

Journal of medicinal chemistry, 1997-03, Vol.40 (7), p.1063-1074

1997

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.4033-4033

2023

Link zum Volltext

Verfügbarkeit prüfen

The total synthesis of the natural product endothelin converting enzyme (ECE) inhibitor, WS75624 B

Tetrahedron letters, 1997-02, Vol.38 (8), p.1297-1300

1997

Link zum Volltext

Verfügbarkeit prüfen

Butenolide Endothelin Antagonists with Improved Aqueous Solubility

Journal of medicinal chemistry, 1999-06, Vol.42 (12), p.2162-2168

1999

Link zum Volltext

Verfügbarkeit prüfen

Reactions of lithiooxazole

Journal of organic chemistry, 1991-01, Vol.56 (1), p.449-452

1991

Link zum Volltext

Verfügbarkeit prüfen

Structure-Activity Relationships of a Novel Series of Orally Active Nonpeptide ETA and ETA/B Endothelin Receptor-Selective Antagonists

Journal of cardiovascular pharmacology, 1995, Vol.26 Suppl 3, p.S358-361

1995

Link zum Volltext

Verfügbarkeit prüfen

Perfluorocarbon-based antidiabetic agents

Journal of medicinal chemistry, 1992-03, Vol.35 (5), p.944-953

1992

Link zum Volltext

Verfügbarkeit prüfen

Ribose-modified adenosine analogs as adenosine receptor agonists

Journal of medicinal chemistry, 1986-03, Vol.29 (3), p.346-353

1986

Link zum Volltext

Verfügbarkeit prüfen

A dramatic solvent effect during aromatic halogen-metal exchanges. Different products from lithiation of polyfluorobromobenzenes in ether and tetrahydrofuran

Journal of organic chemistry, 1990-01, Vol.55 (2), p.773-775

1990

Link zum Volltext

Verfügbarkeit prüfen

Characterization of [125I]‐PD164333, an ETA selective non‐peptide radiolabelled antagonist, in normal and diseased human tissues

British journal of pharmacology, 1998-01, Vol.123 (2), p.223-230

1998

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1)

Bioorganic & medicinal chemistry letters, 1998-08, Vol.8 (16), p.2117-2122

1998

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of novel substituted pyridines as inhibitors of endothelin coverting enzyme-1 (ECE-1)

Bioorganic & medicinal chemistry letters, 1998-08, Vol.8 (16), p.2117-2122

1998

Link zum Volltext

Verfügbarkeit prüfen

A dramatic solvent effect during aromatic halogen-metal exchanges. Different products from lithiation of polyfluorobromobenzenes in ether and THF

Journal of organic chemistry, 1990-01, Vol.55 (2), p.773-775

1990

Link zum Volltext

Verfügbarkeit prüfen

γ-Carbamate butenolide analogues as potent ET A selective endothelin receptor antagonists and prodrugs

Bioorganic & medicinal chemistry letters, 1997-02, Vol.7 (3), p.297-302

1997

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated Drug Resistance via Balanced Inhibition of MET, TIE2, and VEGFR2

Discovery of acyl ureas as highly selective small molecule CSF1R kinase inhibitors

Structure-activity relationships of a series of 2-amino-4-thiazole-containing renin inhibitors

Discovery of a Novel Series of Orally Active Non-Peptide Endothelin-A (ETA) Receptor-Selective Antagonists

Discovery of (pyridin-4-yl)-2H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region

Characterization of [ 125 I]‐PD164333, an ET A selective non‐peptide radiolabelled antagonist, in normal and diseased human tissues

Inhibitors of lipoprotein(a) assembly

Structure−Activity Relationships in a Series of Orally Active γ-Hydroxy Butenolide Endothelin Antagonists

Abstract 4033: Pan-exon mutant KIT inhibitor DCC-3009 demonstrates tumor regressions in preclinical gastrointestinal stromal tumor models

The total synthesis of the natural product endothelin converting enzyme (ECE) inhibitor, WS75624 B

Butenolide Endothelin Antagonists with Improved Aqueous Solubility

Reactions of lithiooxazole

Structure-Activity Relationships of a Novel Series of Orally Active Nonpeptide ETA and ETA/B Endothelin Receptor-Selective Antagonists

Perfluorocarbon-based antidiabetic agents

Discovery of (pyridin-4-yl)-2 H-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis

Ribose-modified adenosine analogs as adenosine receptor agonists

A dramatic solvent effect during aromatic halogen-metal exchanges. Different products from lithiation of polyfluorobromobenzenes in ether and tetrahydrofuran

Characterization of [125I]‐PD164333, an ETA selective non‐peptide radiolabelled antagonist, in normal and diseased human tissues

Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1)

Synthesis of novel substituted pyridines as inhibitors of endothelin coverting enzyme-1 (ECE-1)

A dramatic solvent effect during aromatic halogen-metal exchanges. Different products from lithiation of polyfluorobromobenzenes in ether and THF

γ-Carbamate butenolide analogues as potent ET A selective endothelin receptor antagonists and prodrugs

Suchergebnisse filtern